Strategic and Statistical Considerations on the QT Assessment of Volasertib

Area of Science:

• Pharmacology
• Cardiology
• Oncology

Background:

• Volasertib is a selective cell cycle kinase inhibitor targeting Polo-like kinase (Plk).
• Preclinical and preliminary clinical data suggested a potential for volasertib to prolong QT intervals.
• Electrocardiograms (ECGs) are crucial for monitoring cardiac effects of investigational drugs like volasertib.

Purpose of the Study:

• To describe strategic and statistical methods for an integrated analysis of ECG data from volasertib trials.
• To evaluate volasertib's effect on cardiac repolarization, specifically QT interval duration.
• To address challenges in QT risk assessment when a thorough QT/QTc trial is not feasible.

Main Methods:

• Integrated analysis of ECG data from multiple volasertib clinical trials.
• Prospective planning of statistical methods to handle trial heterogeneity.
• Evaluation of QT interval duration and other ECG-related endpoints.

Main Results:

• Volasertib therapy was associated with a relevant prolongation of the adjusted mean QTcF change from baseline.
• The observed effects on mean QTc changes were transient, resolving within 24 hours after the first infusion.
• No evidence of long-term impact on QTcF interval was found after multiple volasertib infusions.

Conclusions:

• Volasertib causes transient QT interval prolongation, with effects resolving within 24 hours.
• The integrated ECG analysis provides a viable alternative approach for QT risk assessment of investigational drugs.
• These findings support the safety profile of volasertib concerning cardiac repolarization in the short term.